Compare Advanced Micro Devices (AMD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs TG Therapeutics Inc — how do they compare? Advanced Micro Devices trades at $486.25 (market cap $774.32B), while TG Therapeutics Inc trades at $49.95 (market cap $7.64B). The key difference: Advanced Micro Devices is far larger — about 101.4× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| AMD | TGTX | |
|---|---|---|
Market Cap | $774.32B | $7.64B |
Sector | Technology | Health |
52-Week High | $580.91 | $59.06 |
52-Week Low | $151.14 | $26.94 |
Enterprise Value | $765.48B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD's stock trades at $469.56, down 2.86% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.66, and shows robust revenue growth, with 2025 revenue reaching $34.64 billion and net income of $4.34 billion. Valuation ratios remain elevated, with a P/E of 121 and P/S of 18.94, reflecting high market expectations amid surging AI demand.
Outlook is supported by AI-driven growth and consistent earnings beats, but risks include intense competition and rich valuations. Analysts maintain a bullish consensus with a $619.54 price target, though near-term volatility may persist due to technical pressure and macroeconomic factors.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
